Precision BioSciences (NASDAQ:DTIL) stock gains as company reports promising Phase 1 trial results for its Hepatitis B gene ...
Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...
Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation ... particularly B-cell depleting agents like rituximab, or disease. HBsAg-positivity ...
News Medical on MSN9h
Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinomaHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.
Screening for hepatitis B virus is the first crucial step for patients ... Patients on anthracycline derivatives, anti-IL-6 therapies, anti-T cell therapies, or CAR-T cell therapies.
Explore how the liver functions, common liver conditions, and tips to maintain liver health through lifestyle changes like ...
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback